

Results of the votes of the Combined Shareholders' General Meeting of January 30, 2026

Aix-en-Provence, February 2, 2026 – 7:30 a.m. CET – Carvolix (formerly Affluent Medical) (ISIN: FR0013333077 – Ticker: AFME – “Carvolix” or the “Company”), a French commercial and clinical-stage medical technology company specializing in the international development and industrialization of breakthrough AI-driven mini-robots and biomimetic implants, to revolutionize interventional cardiology and the treatment of brain stroke, is today announcing the results of the votes of its Combined Shareholders' Meeting.

The Combined Shareholders' Meeting was held on Friday January 30, 2026, at 11 a.m. at the registered office of the Company located 320 avenue Archimède - Les Pleiades III Batiment B -13100 AIX-EN-PROVENCE (France), under the chairmanship of Mr. Michel Thérin, Chairman of the Board of Directors (the “Board”).

The shareholders have adopted the resolution regarding the change of Company's name as well as all the resolutions supported by the Board, and particularly the delegations granted to the Board related to financial transactions.

The shareholders have also ratified the appointment of Mr. Alain Chevallier as a Board member, and approved the agreements and commitments referred to in Articles L.225-38 and seq. of the Commercial Code.

Details of the vote results are detailed below :

Number of shares with voting rights	39 350 192
Total number of votes	57 009 926
Number of shareholders present, represented or voting by post	33
Number of shares present, represented or voting by post	35 446 196
Number of votes present, represented or voting by post	52 614 168
Participation rate	92.3 %

	Extraordinary General Shareholders' Meeting	For		Against		Abstain	
		Votes	%	Votes	%	Votes	%
1.	Change of the Company's name;	51 756 208	98.37%	857 960	1.63%	0	-
2.	Delegation of powers to the Board of Directors to decide, subject to a condition precedent, on a cash capital increase with the removal of preferential subscription rights in favor of named persons, in one or more instalments, for a maximum nominal amount of €1,238,447.00;	52 614 168	100.00%	0	0.00%	0	-
3.	Removal of preferential subscription rights in favor of Truffle BioMedTech Crossover;	45 655 421	100.00%	0	0.00%	6 958 747	-
4.	Removal of preferential subscription rights in favor of Truffle Innov FRR;	51 015 787	100.00%	0	0.00%	1 598 381	-
5.	Removal of preferential subscription rights in favor of Truffle Medeor;	42 317 293	100.00%	0	0.00%	10 296 875	-

Extraordinary General Shareholders' Meeting	For		Against		Abstain	
	Votes	%	Votes	%	Votes	%
6. Delegation of powers to the Board of Directors to decide, subject to a condition precedent, on a cash capital increase with removal of preferential subscription rights in favor of named persons, on one or more instalments, for a maximum nominal amount of €1,428,398.50;	52 614 167	100.00%	0	0.00%	1	-
7. Removal of preferential subscription rights in favor of Truffle BioMedTech Crossover;	45 655 421	100.00%	0	0.00%	6 958 747	-
8. Removal of preferential subscription rights in favor of Truffle Innov FRR;	51 015 787	100.00%	0	0.00%	1 598 381	-
9. Removal of preferential subscription rights in favor of Truffle Medeor;	42 317 293	100.00%	0	0.00%	10 296 875	-
10. Delegation of authority to the Board of Directors to decide, subject to a condition precedent, on a cash capital increase, in one or more instalments, for a maximum nominal amount of €310,730.50;	52 614 167	100.00%	0	0.00%	1	-
11. Removal of preferential subscription rights in favor of Truffle Medeor;	42 317 293	100.00%	0	0.00%	10 296 875	-
12. Removal of preferential subscription rights in favor of Financière Memnon;	48 867 927	100.00%	0	0.00%	3 746 241	-
13. Cancellation of preferential subscription rights in favor of HAYK Holding Sàrl;	52 414 167	100.00%	0	0.00%	200 001	-
14. Removal of preferential subscription rights in favor of Ginko Invest;	51 568 230	100.00%	0	0.00%	1 045 938	-
15. Removal of preferential subscription rights in favor of Ms. Simone Merkle;	51 756 207	100.00%	0	0.00%	857 961	-
16. Delegation of powers to the Board of Directors to decide, subject to a condition precedent, on a cash capital increase with removal of preferential subscription rights in favor of named persons, in one or more instalments, for a maximum nominal amount of €427,350.30;	52 614 168	100.00%	0	0.00%	0	-
17. Removal of preferential subscription rights in favor of Truffle BioMedTech Crossover;	45 655 421	100.00%	0	0.00%	6 958 747	-
18. Removal of preferential subscription rights in favor of Truffle Medeor;	42 317 293	100.00%	0	0.00%	10 296 875	-
19. Removal of preferential subscription rights in favor of Edwards Lifesciences Holding, Inc.;	48 867 927	100.00%	0	0.00%	3 746 241	-
20. Delegation of authority to the Board of Directors to decide on the issue of shares and/or securities giving immediate or future access to the share capital or entitling the holder to a debt security, with removal of shareholders' preferential subscription rights in favor of certain categories of beneficiaries;	52 614 167	100.00%	0	0.00%	1	-
21. Setting of overall limits on the amount of issues made pursuant to the delegations granted;	52 614 168	100.00%	0	0.00%	0	-
22. Delegation of authority granted to the Board of Directors to increase the share capital by issuing ordinary shares or securities giving access to ordinary shares to be issued immediately or in the future by the Company, reserved for members of a company savings plan to be set up by the Company under the conditions provided for in Articles L.3332-18 et seq. of the French Labor Code, with the removal of shareholders' preferential subscription rights;	3 623 188	6.89%	48 990 979	93.11%	1	-

Ordinary General Shareholders' Meeting		For		Against		Abstain	
		Votes	%	Votes	%	Votes	%
23	Ratification of the co-optation of Mr Alain Chevallier as member of the Board of Director;	52 614 167	100.00%	0	0.00%	1	-
24	Approval of the agreements and commitments referred to in Articles L.225-38 et seq. of the Commercial Code;	30 136 979	100.00%	0	0.00%	22 477 189	-
25	Power to carry out the legal formalities.	52 614 167	100.00%	0	0.00%	1	-



About Carvolix

Carvolix is a French medical technologies company, commercial and clinical stage, founded by Truffle Capital, that aims to become a global leader in the treatment of structural heart diseases and brain strokes, world's leading causes of mortality and disability. Carvolix develops novel AI and imaging driven mini-robots that make complex procedures doble by interventional cardiologists, as well as biomimetics heart valves..

For more information, please visit www.affluentmedical.com

Contacts :

CARVOLIX

Sébastien LADET

CEO

investor@carvolix.eu

SEITOSEI.ACTIFIN

Communication financière / relations presse

Ghislaine GASPARETTO / Enora BUDET

+33 (0)6 85 36 76 81 / +33 (0)6 72 17 84 60

ghislaine.gasparetto@seitosei-actifin.com /
enora.budet@seitosei-actifin.com

PRIMATICE

Relations médias France

Thomas ROBOREL de CLIMENS
+33 (0)6 78 12 97 95

thomasdeclimens@primatice.com

MC SERVICES AG

Relations médias Europe

Maximilian SCHUR / Julia BITTNER

+49 (0)211 529252 20 / +49 (0)211 529252 28

affluent@mc-services.eu